CAJ | 학술논문

恶性黑色素瘤目前仍缺少有效的治疗方法,尤其是转移性的晚期肿瘤,长期的生存获益是很罕见的.随着近几十年来的发展,化疗未再显示出明显的生存优势,随着对此种疾病的分子及免疫背景的研究,疫苗、过继性免疫治疗、靶向治疗等获得了迅速的发展,而近几年的靶向治疗研究对诊断为此病的患者产生极大的影响,其中包括了两种单克隆抗体,抗细胞毒性T淋巴细胞相关抗原4(CTLA-4)及程序性死亡分子1(PD-1)抗体.
악성흑색소류목전잉결소유효적치료방법,우기시전이성적만기종류,장기적생존획익시흔한견적.수착근궤십년래적발전,화료미재현시출명현적생존우세,수착대차충질병적분자급면역배경적연구,역묘、과계성면역치료、파향치료등획득료신속적발전,이근궤년적파향치료연구대진단위차병적환자산생겁대적영향,기중포괄료량충단극륭항체,항세포독성T림파세포상관항원4(CTLA-4)급정서성사망분자1(PD-1)항체.
The effective treatment toward malignant melanoma is still lacking,particularly about metastatic melanoma.Therefore,long-term survival of patients is very rare.Chemotherapy has not shown a significant advantage in the past decades.However,along with the study of the molecular and immunologic background of the disease,vaccine,adoptive immunotherapy and targeted therapy have developed rapidly.The targeted therapy,including the application of immune modulators against cytotoxic T lymphocyte associated antigen-4(CTLA-4) and programmed death-1 (PD-1),has exerted an enormous effect on patients with malignant melanoma.